Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Ultragenyx Pharmaceutical Inc. RARE

Ultragenyx Pharmaceutical Inc is a US-based biopharmaceutical company. It identifies, acquires, develops, and commercialize novel products for the treatment of serious rare and ultra-rare diseases, with the focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older.


Recent & Breaking News (NDAQ:RARE)

28th Annual Emerald Groundhog Day Investment Forum Goes Virtual as Pandemic Casts a Long Shadow

Business Wire January 14, 2021

Ultragenyx Reports Preliminary 2020 Revenue and 2021 Revenue Guidance for Crysvita in Ultragenyx Territories

GlobeNewswire January 11, 2021

Ultragenyx Announces Progress Across Broad Gene Therapy Portfolio and Positive Longer-Term Data from Multiple Phase 1/2 Gene Therapy Studies

GlobeNewswire January 8, 2021

Ultragenyx to Present at 39th Annual J.P. Morgan Virtual Healthcare Conference

GlobeNewswire January 5, 2021

Ultragenyx and Mereo BioPharma Announce Collaboration and License Agreement for Setrusumab in Osteogenesis Imperfecta

GlobeNewswire December 17, 2020

Mereo BioPharma and Ultragenyx Announce Collaboration and License Agreement for Setrusumab in Osteogenesis Imperfecta

GlobeNewswire December 17, 2020

Ultragenyx Announces Orphan Drug Designation for UX701 for the Treatment of Wilson Disease

GlobeNewswire December 9, 2020

GeneTx and Ultragenyx Announce Presentation of Phase 1/2 Data on Investigational GTX-102 in Patients with Angelman Syndrome

GlobeNewswire December 5, 2020

Ultragenyx to Present at Upcoming Healthcare Conferences

GlobeNewswire November 24, 2020

Ultragenyx Announces Plans to Build Large-scale Gene Therapy Manufacturing Facility to Support Pipeline of Therapies for Rare Diseases

GlobeNewswire November 9, 2020

Ultragenyx to Present at Upcoming Investor Conferences

GlobeNewswire November 5, 2020

Ultragenyx Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

GlobeNewswire November 2, 2020

Ultragenyx Announces Pricing of Public Offering of Common Stock

GlobeNewswire October 28, 2020

Ultragenyx Announces Proposed Public Offering of Common Stock

GlobeNewswire October 28, 2020

Ultragenyx Reports Third Quarter 2020 Financial Results and Corporate Update

GlobeNewswire October 27, 2020

GeneTx and Ultragenyx Announce Positive Interim Phase 1/2 Data on Investigational GTX-102 Demonstrating Improvement in Patients with Angelman Syndrome

GlobeNewswire October 26, 2020

Ultragenyx and Solid Biosciences Announce Strategic Collaboration to Develop and Commercialize New Gene Therapies for Duchenne Muscular Dystrophy

GlobeNewswire October 23, 2020

Ultragenyx to Host Conference Call for Third Quarter 2020 Financial Results and Corporate Update

GlobeNewswire October 21, 2020

Ultragenyx to Present at Jefferies Gene Therapy/Editing Summit

GlobeNewswire September 25, 2020

Ultragenyx to Present at Upcoming Investor Conferences

GlobeNewswire September 3, 2020